www.fdanews.com/articles/127221-santhera-rsquo-s-trial-for-friedreich-rsquo-s-ataxia-misses-endpoint

Santhera’s Trial for Friedreich’s Ataxia Misses Endpoint

May 20, 2010

Santhera Pharmaceuticals announced Thursday that its MICONOS Phase III study evaluating Catena/Sovrima for the treatment of Friedreich’s Ataxia missed its primary endpoint.
iStockAnalyst